Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avenanthramide C is a naturally occurring bioactive polyphenol and small molecule isolated from oat seeds (*Avena sativa* L.). It is characterized by its potent anti-inflammatory, antioxidant, anti-apoptotic, and neuroprotective properties. Mechanistically, it suppresses pro-inflammatory signaling pathways such as NF-κB and TNF-α, reduces reactive oxygen species (ROS), and modulates apoptotic markers like cleaved caspase-3. Preclinical research has explored its potential in treating Alzheimer's disease, protecting against noise- and drug-induced hearing loss, and mitigating cisplatin-induced toxicities, including neurotoxicity ('chemobrain') and cardiotoxicity. Additionally, it has been investigated for dermatological applications, specifically for improving skin tone and reducing hyperpigmentation in atopic dermatitis by inhibiting tyrosinase and melanogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avenanthramide c.